Cite
Colon-Targeted Delivery Facilitates the Therapeutic Switching of Sofalcone, a Gastroprotective Agent, to an Anticolitic Drug via Nrf2 Activation
MLA
Kim, Wooseong, et al. “Colon-Targeted Delivery Facilitates the Therapeutic Switching of Sofalcone, a Gastroprotective Agent, to an Anticolitic Drug via Nrf2 Activation.” Molecular Pharmaceutics, vol. 16, no. 9, Sept. 2019, pp. 4007–16. EBSCOhost, https://doi.org/10.1021/acs.molpharmaceut.9b00664.
APA
Kim, W., Kim, S., Ju, S., Lee, H., Jeong, S., Yoo, J.-W., Yoon, I.-S., & Jung, Y. (2019). Colon-Targeted Delivery Facilitates the Therapeutic Switching of Sofalcone, a Gastroprotective Agent, to an Anticolitic Drug via Nrf2 Activation. Molecular Pharmaceutics, 16(9), 4007–4016. https://doi.org/10.1021/acs.molpharmaceut.9b00664
Chicago
Kim, Wooseong, Soojin Kim, Sanghyun Ju, Hanju Lee, Seongkeun Jeong, Jin-Wook Yoo, In-Soo Yoon, and Yunjin Jung. 2019. “Colon-Targeted Delivery Facilitates the Therapeutic Switching of Sofalcone, a Gastroprotective Agent, to an Anticolitic Drug via Nrf2 Activation.” Molecular Pharmaceutics 16 (9): 4007–16. doi:10.1021/acs.molpharmaceut.9b00664.